152 related articles for article (PubMed ID: 36777381)
1. Cost-effectiveness of stereotactic body radiotherapy versus conventional radiotherapy for the treatment of surgically ineligible stage I non-small cell lung cancer in the Brazilian public health system.
Arruda GV; Lourenção M; de Oliveira JHC; Galendi JSC; Jacinto AA
Lancet Reg Health Am; 2022 Oct; 14():100329. PubMed ID: 36777381
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hypofractionated versus conventional fractionated radiotherapy for the treatment of men with early glottic cancer: a study in the Brazilian public and private health system.
Lourenção M; Arruda GV; Rocha LP; Galendi JSC; de Oliveira JC; Jacinto AA
BMC Health Serv Res; 2023 Jun; 23(1):592. PubMed ID: 37291564
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancer.
Sun H; Wang H; Wei Y; Wang H; Jin C; Chen Y
Cost Eff Resour Alloc; 2023 Jul; 21(1):46. PubMed ID: 37507748
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer.
Mitera G; Swaminath A; Rudoler D; Seereeram C; Giuliani M; Leighl N; Gutierrez E; Dobrow MJ; Coyte PC; Yung T; Bezjak A; Hope AJ
J Oncol Pract; 2014 May; 10(3):e130-6. PubMed ID: 24643574
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
Paix A; Noel G; Falcoz PE; Levy P
Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC).
Donovan EK; Xie F; Louie AV; Chu W; Siva S; Kapoor A; Swaminath A
Clin Genitourin Cancer; 2022 Oct; 20(5):e353-e361. PubMed ID: 35490099
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
Sher DJ; Wee JO; Punglia RS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
Wolff HB; Alberts L; van der Linden N; Bongers ML; Verstegen NE; Lagerwaard FJ; Hofman FN; Uyl-de Groot CA; Senan S; El Sharouni SY; Kastelijn EA; Schramel FMNH; Coupé VMH
Lung Cancer; 2020 Mar; 141():89-96. PubMed ID: 31982640
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer.
Yang J; Qi SN; Fang H; Song YW; Jin J; Liu YP; Wang WH; Yang Y; Tang Y; Ren H; Chen B; Lu NN; Tang Y; Li N; Jing H; Wang SL; Li YX
Breast; 2021 Aug; 58():72-79. PubMed ID: 33933925
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases.
Kim H; Gill B; Beriwal S; Huq MS; Roberts MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1175-83. PubMed ID: 27130789
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck.
Leung HW; Lang HC; Wang SY; Leung JH; Chan AL
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):489-495. PubMed ID: 33729079
[TBL] [Abstract][Full Text] [Related]
13. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
Simoes Correa-Galendi J; Del Pilar Estevez Diz M; Stock S; Müller D
Appl Health Econ Health Policy; 2021 Jan; 19(1):97-109. PubMed ID: 32537695
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
[TBL] [Abstract][Full Text] [Related]
17. Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.
Wu X; Uhlig J; Blasberg JD; Gettinger SN; Suh RD; Solomon SB; Kim HS
J Vasc Interv Radiol; 2022 Aug; 33(8):964-971.e2. PubMed ID: 35490932
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis.
Helou J; Torres S; Musunuru HB; Raphael J; Cheung P; Vesprini D; Chung HT; D'Alimonte L; Krahn M; Morton G; Loblaw A
Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):718-731. PubMed ID: 28916284
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility of stereotactic radiation therapy
Leung HWC; Chan ALF
Oncotarget; 2017 Sep; 8(43):75568-75576. PubMed ID: 29088891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
